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Abstract 1 
Background: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the 2 
management of dementia. In routine clinical practice dementia is often monitored via the mini-mental 3 
state examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these 4 
drugs on MMSE scores. Summary: Eighty trials were identified. Pooled effect estimates were in favour 5 
of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia sub-type was a 6 
moderator of AChEI treatment effect with the effect of treatment versus control twice as high for 7 
PDD/DLB patients (2.11 MMSE points at 6 months) as for AD/VaD patients (0.91 MMSE points at 6 8 
months). Key messages: AChEIs demonstrate a modest effect versus control on MMSE scores which is 9 
moderated by dementia sub-type. For memantine the effect is smaller. 10 
Introduction 11 
Dementia is a major health concern in elderly populations worldwide which can affect many aspects of a 12 
person’s life and functioning. There is currently no cure for most forms of dementia but several drugs 13 
are used in its management. The acetylcholinesterase inhibitors (AChEIs) were developed as a 14 
consequence of the cholinergic hypothesis of cognitive decline [1] and the NMDA receptor agonist 15 
memantine as a consequence of an hypothesised role of the glutamatergic system in neurodegeneration 16 
[2]. The effectiveness of these treatments has been evaluated in a large number of randomised 17 
controlled trials (RCTs) across functional, global, cognitive and neuropsychiatric domains [3-5]. This 18 
review focuses on their effects on cognition.  19 
Measures  of global cognition include the mini-mental state examination (MMSE) [6], the Alzheimer’s 20 
disease assessment scale - cognitive subscale (ADAS-cog) [7], and the Severe Impairment Battery (SIB) 21 
[8], which focuses on those with severe cognitive impairment. Existing meta-analyses tend either to 22 
consider cognitive outcomes on the ADAS-cog or SIB [9] or to use standardised mean differences to 23 
combine results from several scales [10]. In this review results are analysed relating to the MMSE scale 24 
specifically. A small number of existing meta-analyses combine cognitive outcomes on the MMSE; 25 
however, these are mainly focused in diagnostic and medication subgroups and do not cover all 26 
available trials. The largest of these includes only 21 MMSE effect estimates [11], less than half of the 27 
number included in this review. 28 
The MMSE is the scale which is most often used in routine clinical practice to monitor dementia severity 29 
and progression and thus the advantage of reviewed outcomes on this scale is better clinical 30 
interpretability and relevance to routine care.  In addition the volume of evidence can be substantially 31 
increased by the inclusion of ADAS-cog results translated to MMSE scale equivalents. 32 
Methods 33 
A protocol for this systematic review was prospectively registered on PROSPERO and can be found at 34 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015025892.  35 
Search strategy 36 
A two-tier search strategy was employed to identify relevant trials for inclusion in this review. First, 1 
existing systematic reviews and meta-analyses assessing the drugs of interest were identified and 2 
citations to included trials extracted. Following this, additional searches subdivided by dementia 3 
diagnosis and, where necessary, drug received, were conducted to identify trials published since the 4 
date of the most recent review. 5 
Searches were conducted using the Web of Science, MEDLINE, PsycINFO, EMBASE and CINAHL 6 
databases. Final searches were conducted in March 2017. Searches were combinations of; (i) drug 7 
names e.g. “donepezil”, “galantamine”, “rivastigmine”, “memantine”; (ii) diagnoses e.g. “Alzheimer*”, 8 
“vascular dement*”, “lewy* bod*”, “Parkinson* disease dement*”; and (iii) “randomi?ed” and “trial”. A 9 
full list of search terms used is provided in the supplementary material. Further searches were carried 10 
out using the International Clinical Trials Registry Platform (ICTRP) and industry trial registers to identify 11 
unpublished trials, and references and citing articles of selected trials were assessed to identify further 12 
trials for inclusion.  13 
Study selection criteria and data extracted 14 
Trials were included if they met the following criteria: (i) a randomised trial designed to evaluate the 15 
effectiveness of AChEI monotherapy, memantine monotherapy or memantine treatment in a group of 16 
patients some, but not all, of whom received a concurrent AChEI; (ii) treatments compared to a control 17 
group receiving placebo or no treatment; (iii) participants in the trial diagnosed with Alzheimer’s disease 18 
(AD), vascular dementia (VaD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB) or 19 
frontotemporal dementia (FTD); (iv) at least one of the MMSE or ADAS-cog used as an outcome; and (v) 20 
sufficient data provided, defined as at least one treatment effect estimate and associated standard error 21 
(SE) on either the MMSE or ADAS-cog. Treatment effect estimates used included change score 22 
differences and time point differences. In some cases, effect estimates and SEs had to be calculated 23 
from other statistics (for example, confidence intervals). 24 
 25 
From each trial data were extracted on: (i) Trial design – duration, inclusion and exclusion criteria, 26 
numbers of patients randomised to each arm, intervention and control conditions, type of 27 
randomisation, details on blinding, cognitive assessments and measurement times; (ii) Analysis 28 
approaches – analysis method, missing data methods and effect size estimate used; and (iii) Trial data – 29 
baseline data, attrition and adherence rates, treatment effect estimates and SEs.  30 
 31 
Study selection and data extraction were conducted by one reviewer (RK) and a sample of each was 32 
checked by a second reviewer (NM). Reviewers agreed on study selection in 99% of cases and 33 
agreement regarding data extraction was also high: 87.5% for risk of bias assessment, 82.8% for baseline 34 
measures and 75% for effect estimates. Most effect estimate discrepancies were due to 35 
miscommunication on how these were extracted. All discrepancies were discussed and resolved. 36 
 37 
ADAS-cog translation 38 
 39 
The objective of the meta-analysis was to estimate the treatment effect on the MMSE; however, effect 1 
estimates on the ADAS-cog were also collected and translated, since both scales measure global 2 
cognition. Baseline measures from the 36 trials which measured both were used to translate. MMSE 3 
scores range from 0 to 30 and ADAS-cog scores from 0 to 70 and both MMSE=30 and ADAS-cog=0 4 
represent healthy cognition. Thus a linear regression of ADAS-cog on MMSE with intercept fixed at 30 5 
was fitted. The resulting model was: MMSE=30-0.42*ADAS-cog, with a squared multiple correlation of 6 
0.679 suggesting fairly good fit. Translation of both treatment effect estimates and SEs required only the 7 
coefficient. Treatment effect estimates were translated using MMSE=-0.42*ADAS-cog, and the SEs using 8 
MMSE=0.42*ADAS-cog. 9 
 10 
Risk of bias assessment 11 
The risk of bias in included studies was assessed using the Cochrane risk of bias tool [12]. This 12 
determines whether the risk of internal bias under a series of domains is low, high or unclear. These 13 
were combined so that a trial rated low in all domains was at low risk of bias. One domain, reporting 14 
bias, was excluded from the combination since trial protocols were required to assess it but were not 15 
available for most included trials due to their age. 16 
Statistical analyses 17 
Random-effects meta-analysis [13] was used to combine trial results. This was conducted separately for 18 
AChEIs and memantine. Pooled effects were estimated at 3, 6 and 12 months (+14 days) after treatment 19 
initiation. Effect estimates were also considered in AChEI drug subgroups. Heterogeneity was assessed 20 
using the I2 statistic [14] and publication bias using funnel plots and Begg and Mazumdar’s [15] rank 21 
correlation test. All statistical analyses were conducted using R [16] and the metafor package [17]. 22 
Meta-regressions were conducted to assess the impact of data quality on effect size estimates and test 23 
potential moderators. The data quality factors were: (i) the inclusion of translated results; and (ii) the 24 
risk of bias assessment overall rating. The hypothesised potential moderators were: (i) AChEI (donepezil, 25 
galantamine or rivastigmine); (ii) dementia diagnosis (AD, VaD, PDD/DLB or FTD); (iii) baseline MMSE 26 
score; and (iv) date of publication (before or after 2000). All were categorical factors except baseline 27 
MMSE which was continuous. The Knapp and Hartung [18] adjustment was used to account for 28 
uncertainty in the assessment of residual heterogeneity. The omnibus test of coefficients was used to 29 
identify factors significant at the 5% and 1% levels. 30 
Results 31 
Literature search results 32 
The search for systematic reviews identified 522 citations of which 52 were relevant, and these included 33 
194 citations to trials. An additional 857 citations were identified by further searches for trials resulting 34 
in 1051 possible citations. After removal of duplicates, title and abstract screening, and full text 35 
screening, 84 references about 74 trials met the inclusion criteria. Searches in ICTRP and industry 36 
registers and citation tracking identified a further 6 trials for inclusion. In total, 80 trials met the 1 
inclusion criteria. The process of identifying these is detailed in Figure 1.  2 
Characteristics of included studies 3 
Of the included trials summarised in Table 1, half (40) investigated donepezil and the others were evenly 4 
split amongst galantamine (13), rivastigmine (14) and memantine (13). The majority of the trials (55) 5 
were conducted in patients with AD. Other diagnoses were VaD (9), AD and VaD (4), PDD or DLB (10) 6 
and FTD (2). Dementia severity ranged from mild in some trials to severe in others. The trials lasted 7 
between 4 and 104 weeks and many recorded outcome measures at intermediate time points. Forty 8 
eight trials provided MMSE outcomes, 24 ADAS-cog and the remainder reported a mixture of the two.  9 
The average baseline age in AChEI trials was 73.8 years and in memantine trials was 75.9 years. The 10 
proportion of women was slightly more than half in the AChEI trials (mean 57.5%; range 7.1%-84.6%), 11 
and the memantine trials ( mean 56.3%; range 25%-73.8%). The mean baseline MMSE was higher in the 12 
AChEI trials (18.6 points) than the memantine trials (16.5). 13 
Risk of bias assessment 14 
The Cochrane risk of bias tool was applied to each trial and the final column of Table 1 records overall 15 
ratings. Risk of bias was low in 14 trials, high in 45 trials and unclear in 21 trials. The large number of 16 
trials rated high risk was mainly due to missing data methods combined with relatively high volumes of 17 
missing data. The majority of trials used observed case or last observation carried forward analyses 18 
which both introduce a significant risk of bias in the presence of missing data. 19 
Meta-analysis results 20 
AChEIs – 3 months 21 
At 3 months (+14 days) after treatment initiation, 42 trials provided 60 estimates of treatment effect. 22 
The pooled effect estimate (Figure 2) was 1.08 MMSE points (95% CI 0.92-1.23). There was evidence of 23 
heterogeneity (I2=68.2%) and this was later explored via meta-regression. Begg and Mazumdar’s rank 24 
test suggested some publication bias (p=0.01) and the funnel plot supported this (Figure 3), however the 25 
patterns did not seem overly concerning. In the drug subgroups the treatment effects ranged from 0.98 26 
(95% CI 0.32-1.63) for rivastigmine to 1.15 (95% CI 0.69-1.61) for donepezil 3-5mg/d. 27 
AChEIs – 6 months 28 
At 6 months (+14 days) after treatment initiation, 38 trials provided 52 estimates of treatment effect. 29 
The pooled effect estimate was 1.00 (95% CI 0.83-1.16; Figure 4), and there was evidence of 30 
heterogeneity (I2=69.9%). Neither the funnel plot nor the rank correlation test (p=0.385) suggested 31 
publication bias. The effect estimates in treatment subgroups ranged from 0.69 (95% CI 0.43-0.95) for 32 
rivastigmine to 1.39 (95% CI 0.79-2.00) for galantamine. 33 
AChEIs – 12 months 34 
At 12 months (+14 days) after treatment initiation, 4 trials provided estimates of treatment effect. The 1 
pooled effect estimate was 1.10 (95% CI 0.48-1.72; Figure 5). There was evidence for heterogeneity 2 
(I2=79%); however, the funnel plot did not suggest any obvious publication bias and there were too few 3 
estimates for a formal test. 4 
Memantine – 3, 6 and 12 months 5 
Treatment effect estimates were provided by 12 memantine trials: 4 at 3 months; 8 at 6 months; and 3 6 
at 12 months after treatment initiation. The pooled effect estimates at each time point were in favour of 7 
treatment though were much smaller than those for the AChEIs (Figure 6). At 12 months the pooled 8 
effect did not reach significance (0.41, 95% CI -0.44 to 1.26). At all 3 time points the I2 values were small 9 
suggesting little heterogeneity. 10 
Meta-regressions 11 
High I2 values observed for the AChEI meta-analyses at 3 and 6 months suggested considerable 12 
variability in the effect estimates and this was investigated further via meta-regression. Factors 13 
investigated were data quality measures and potential moderators as listed in the methods section. 14 
Tables 2 and 3 provide meta-regression coefficients, associated p-values and the p-value for the 15 
omnibus test of parameters at 3 and 6 months respectively. Coefficients are the difference in average 16 
effect estimates for each category versus the reference category for categorical factors and the relation 17 
between the factor and effect estimate for continuous factors. Factors for which the omnibus test of 18 
parameters is significant at the 5% and 1% levels are highlighted.  19 
A true moderator of treatment effect would be expected to last over time, thus only factors significant 20 
at both 3 and 6 months were considered. Dementia sub-type diagnosis was the only factor significant at 21 
both 3 months (p=0.009) and 6 months (p=0.007). Examination of diagnostic subgroup results suggested 22 
that the effects in the AD and VaD subgroups were the same but those in the PDD/DLB subgroup were 23 
different. 24 
Meta-analyses in diagnosis subgroups 25 
At 3 months the pooled effect estimate in the AD/VaD subgroup was 0.97 MMSE points (95% CI 0.85-26 
1.10) and in the PDD/DLB subgroup 1.99 (1.18-2.81). At 6 months the effect in the AD/VaD subgroup 27 
was 0.91 (0.77-1.05) and in the PDD/DLB subgroup was 2.11 (0.61-3.61). All four trials providing an 28 
effect estimate at 12 months were in the AD/VaD subgroup. The memantine trials provided too few 29 
trials for meta-regression to be conducted; however, at both 6 months and 12 months the effects in the 30 
PDD/DLB subgroup were significantly higher (1.90 points at 6 months and 1.80 points at 12 months) 31 
than those in the AD/VaD subgroup (0.36 points at 6 months and 0.31 points at 12 months). 32 
Discussion  33 
This review identified 80 trials evaluating the effects of donepezil, galantamine, rivastigmine and 34 
memantine on cognitive function in dementia, more than in any previous review. Cognitive effects were 35 
extracted on the MMSE, the outcome of interest, or the ADAS-cog. Baseline measures from 36 trials 36 
which measured both were used to enable translation of ADAS-cog results to the MMSE scale. This 1 
allowed the inclusion of 24 additional trials and results at additional time points from a further 8 trials. 2 
The large number of studies included in this review is one of its strengths and this number is increased 3 
by the translation of ADAS-cog results. The translation relationship has good R2; however, this 4 
relationship has not been used elsewhere and should therefore be treated as preliminary and requiring 5 
confirmation. 6 
Meta-regressions of the AChEI results at 3 and 6 months identified one moderator of treatment effect, 7 
dementia sub-type diagnosis. Treatment effects were smaller for those patients diagnosed with AD or 8 
VaD (0.97 MMSE points at 3 months and 0.91 points at 6 months) than those diagnosed with PDD or DLB 9 
(1.99 points at 3 months and 2.11 points at 6 months).  All trials reporting effects at 12 months were for 10 
AD or VaD patients and these indicated a similar effect to those at 3 and 6 months (1.10 points). The 11 
higher response seen in the PDD/DLB group is consistent with previous results [19] and may be due to 12 
the greater cholinergic deficit seen in these conditions [20]. The effects observed in the AD/VaD 13 
subgroup are somewhat smaller than those in a previous review of AChEIs in AD only [5]. This may be 14 
due to the inclusion of VaD results which evidence suggests may give rise to more mixed findings on 15 
AChEI effect [21, 22], although meta-regression indicated no significant differences between AD and 16 
VaD subgroups. Whilst these drugs are only licensed for the use in AD or PDD there is evidence that they 17 
are widely used for patients with DLB and VaD in routine clinical practice [23] and thus the inclusion of 18 
these trial results was felt to be appropriate. 19 
The number of trials providing estimates of memantine treatment effects was much smaller and it was 20 
not possible to conduct meta-regression analyses; however, results were calculated for the previously 21 
identified subgroups. In the AD/VaD subgroup the effects were small and in favour of treatment (0.65 22 
MMSE points at 3 months, 0.36 points at 6 months and 0.41 points at 12 months). Again the effects in 23 
the PDD/DLB subgroup were higher (1.90 points at 6 months and 1.80 points at 12 months). Few of 24 
these effects were significantly different from zero.  25 
Through the results of this review, we sought to increase clinical interpretability and relevance to 26 
routine care since they are estimated on the MMSE, the scale most often used to monitor dementia in 27 
clinical practice. Estimation of MMSE effects also potentially enables results to be compared, contrasted 28 
and in future combined with observational findings from routine clinical practice. The AChEI results 29 
suggest a treatment effect of around one MMSE point at 3, 6 and 12 months after treatment initiation. 30 
Since studies have suggested that the annual rate of MMSE decline amongst dementia patients is 4 to 5 31 
MMSE points [24] such an effect estimate is modest: equivalent to an approximately 3 month delay in 32 
cognitive decline. However, while the effect sizes are small, they could have a significant impact in terms 33 
of costs and hospital or nursing home admissions which have both been shown to be linked to level of 34 
cognitive function as measured by the MMSE score [25]. In addition the length of time for which these 35 
benefits continue may be of interest [23]. 36 
Use of the MMSE scale makes the results of this review more clinically applicable, however, there are 37 
several limitations to this scale. It suffers from both floor and ceiling effects [26], though these should 38 
not be of particular concern for the trials included in this study. In addition, it is particularly suitable for 39 
measuring the cognitive deficits observed in AD and may be less sensitive to those in VaD [27] or FTD 1 
[28]. However, the latter has little impact in the current review since only one included trial concerned 2 
FTD and, as mentioned, no significant differences were found between AD and VaD sub-groups in meta-3 
regressions. 4 
 5 
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Table 1: Characteristics of included studies (CVD=cerebrovascular disease, CADASIL=Cerebral 1 
Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, PRC=prolonged-2 
release capsule, BID=twice daily, TID=three-times daily) 3 
Study Diagnosis Duration 
(weeks) 
Cognitive 
measure 
Trial arms (n) Risk of bias 
Donepezil 
Frolich et al., 
2011[29] 
AD 12 MMSE 5 or 10mg/d (161) 
Placebo (164) 
Unclear 
Gault et al., 
2015[30] 
AD 12 ADAS-cog 10mg/d (68) 
Placebo (68) 
Low 
Gelmacher et al., 
2000[31] 
AD 12 MMSE Donepezil (6) 
Placebo (6) 
Unclear 
Marek et al., 
2014[32] 
AD 12 MMSE 10mg/d (66) 
Placebo (66) 
High 
Peng et al., 2005[33] AD 12 MMSE 5mg/d (46) 
Placebo (43) 
High 
Rogers et al., 
1998a[34] 
AD 12 MMSE 5mg/d (157) 
10mg/d (158) 
Placebo (153) 
High 
NCT00777608  AD 12 ADAS-cog 5 or 10mg/d (53) 
Placebo (53) 
High 
Howard et al., 
2007[35] 
AD 12 MMSE 10mg/d (128) 
Placebo (131) 
Low 
Moraes et al., 
2008[36] 
AD 13 ADAS-cog 5mg/d (11) 
Placebo (12) 
Unclear 
Sole-Padulles et al., 
2013[37] 
AD 13 MMSE 10mg/d (8) 
Placebo (7) 
High 
Haig et al., 2014[38] AD 14 MMSE 10mg/d (60) 
Placebo (63) 
Low 
Black et al., 2007[39] AD 24 MMSE 10mg/d (176) 
Placebo (167) 
High 
Burns et al., 
1999[40] 
AD 24 ADAS-cog 5mg/d (271) 
10mg/d (273) 
Placebo (274) 
Unclear 
Feldman et al., 
2000[41] 
AD 24 MMSE 10mg/d (144) 
Placebo (146) 
Unclear 
Gold et al., 2010[42] AD 24 ADAS-cog 10mg/d (84) 
Placebo (166) 
High 
Homma et al., 
2000[43] 
AD 24 ADAS-cog 5mg/d (134) 
Placebo (129) 
Unclear 
Jia et al., 2017[44] AD 24 MMSE 5mg/d (156) 
Placebo (156) 
Low 
Maher-Edwards et 
al., 2011[45] 
AD 24 ADAS-cog 10mg/d (67) 
Placebo (63) 
High 
Mazza et al., 
2006[46] 
AD 24 MMSE 5mg/d (25) 
Placebo (26) 
High 
Gault et al., 
2016[47] 
AD 24 MMSE 10mg/d (76) 
Placebo (104) 
Unclear 
Rogers et al., 
1998b[48] 
AD 24 MMSE 
ADAS-cog 
5mg/d (154) 
10mg/d (157) 
Placebo (162) 
High 
Seltzer et al., 
2004[49] 
AD 24 MMSE 
ADAS-cog 
10mg/d (96) 
Placebo (57) 
High 
Tune et al., 2003[50] AD 24 ADAS-cog 10mg/d (14) 
Placebo (14) 
 
Unclear 
Maher-Edwards et 
al., 2015[51] 
AD 24 MMSE 
ADAS-cog 
5 or 10mg/d (152) 
Placebo (145) 
High 
dos Santos Moraes 
et al., 2006[52] 
AD 26 ADAS-cog 10mg/d (17) 
Placebo (18) 
Low 
Winblad et al., 
2006[53] 
AD 26 MMSE 10mg/d (128) 
Placebo (121) 
High 
Winblad et al., 
2001[54] 
AD 52 MMSE 10mg/d (142) 
Placebo (144) 
Unclear 
Mohs et al., 
2001[55] 
AD 54 MMSE 10mg/d (214) 
Placebo (217) 
High 
Bentham et al., 
2004[56] 
AD or 
AD+VaD 
12 MMSE 5mg/d (282) 
Placebo (283) 
High 
Tariot et al., 
2001[57] 
AD or 
AD+CVD 
24 MMSE 10mg/d (103) 
Placebo (105) 
High 
Black et al., 2003[58] VaD 24 MMSE 
ADAS-cog 
5mg/d (198) 
10mg/d (206) 
Placebo (199) 
High 
Roman et al., 
2010[59] 
VaD 24 MMSE 5mg/d (648) 
Placebo (326) 
High 
Wilkinson et al., 
2003[60] 
VaD 24 MMSE 5mg/d (208) 
10mg/d (215) 
Placebo (193) 
High 
Dichgans et al., 
2008[61] 
CADASIL 18 MMSE 10mg/d (86) 
Placebo (82) 
Unclear 
Aarsland et al., 
2002[62]  
PDD 10 MMSE 5 or 10mg/d (8) 
Placebo (6) 
High 
Ravina et al., 
2005[63] 
PDD 10 ADAS-cog 5mg/d (11) 
Placebo (11) 
High 
Leroi et al., 2004[64] PDD 18 MMSE 10mg/d (7) 
Placebo (9) 
Unclear 
Dubois et al., 
2012[65] 
PDD 24 MMSE 
ADAS-cog 
5mg/d (195) 
10mg/d (182) 
Placebo (173) 
High 
Ikeda et al., 
2015[66] 
DLB 12 MMSE 5mg/d (46) 
10mg/d (47) 
Placebo (49) 
High 
 
Mori et al., 2012[67] DLB 12 MMSE 3mg/d (35) 
5mg/d (33) 
Low 
10mg/d (37) 
Placebo (35) 
Galantamine 
Wilkinson and 
Murray, 2001[68] 
AD 12 ADAS-cog 18mg/d (88) 
24mg/d (56) 
36mg/d (54) 
Placebo (87) 
High 
Kadir et al., 2008[69] AD 13 MMSE 8-16mg/d (12) 
Placebo (6) 
Unclear 
Rockwood et al., 
2001[70] 
AD 13 ADAS-cog 24-32mg/d (261) 
Placebo (125) 
High 
Rockwood et al., 
2006[71] 
AD 16 ADAS-cog 16-24mg/d (64) 
Placebo (66) 
Unclear 
Tariot et al., 
2000[72] 
AD 22 ADAS-cog 8mg/d (140) 
16mg/d (279) 
24mg/d (273) 
Placebo (286) 
Unclear 
Brodaty et al., 
2005[73] 
AD 26 ADAS-cog 16-24mg/d (237) 
16-24mg/d PRC (320) 
Placebo (324) 
High 
Raskind et al., 
2000[74] 
AD 26 ADAS-cog 24mg/d (212) 
32mg/d (211) 
Placebo (213) 
High 
Wilcock et al., 
2000[75] 
AD 26 ADAS-cog 24mg/d (220) 
32mg/d (218) 
Placebo (215) 
High 
Likitjaroen et al., 
2011[76] 
AD 26 MMSE 16mg/d (14) 
Placebo (11) 
Unclear 
Hager et al., 
2014[77] 
AD or 
AD+CVD 
104 MMSE 18-24mg/d (1028) 
Placebo (1023) 
Low 
Erkinjuntti et al.,  
2002[78] 
VaD or 
AD+CVD 
26 ADAS-cog 24mg/d (396) 
Placebo (196) 
High 
Auchus et al., 
2007[79] 
VaD 26 ADAS-cog 24mg/d (397) 
Placebo (391) 
High 
Litvinenko et al., 
2008[80]  
PDD 24 MMSE 16mg/d (21) 
Placebo (20) 
High 
Rivastigmine      
Koch et al., 2014[81] AD 4 MMSE 4.6mg/d (10) 
Placebo (10) 
Unclear 
Mowla et al., 
2007[82] 
AD 12 MMSE 6-12mg/d (41) 
Placebo (40) 
Unclear 
Iranmanesh et al., 
2012[83] 
AD 12 MMSE 3mg/d (16) 
Placebo (16) 
Unclear 
Agid et al., 1998[84] AD 13 MMSE 4mg/d (136) 
6mg/d (133) 
Placebo (133) 
High 
Forette et al., 
1999[85] 
AD 18 ADAS-cog 12mg/d BID (45) 
12mg/d TID (45) 
High 
Placebo (24) 
Winblad et al., 
2007[86] 
AD 24 MMSE 12mg/d capsule (297) 
9.5mg/d patch (293) 
17.4mg/d patch (303) 
Placebo (302) 
High 
NCT00423085 AD 24 MMSE 9mg/d patch (284) 
18mg/d patch (287) 
Placebo (288) 
High 
Rosler et al., 
1999[87] 
AD 26 MMSE 1-4mg/d (243) 
6-12 mg/d (243) 
Placebo (239) 
High 
Corey-Bloom et al., 
1998[88] 
AD 26 MMSE 
ADAS-cog 
1-4mg/d (233) 
6-12 mg/d (231) 
Placebo (235) 
High 
Feldman and Lane, 
2007[89] 
AD 26 MMSE 
ADAS-cog 
2-12mg/d BID (229) 
2-12mg/d TID (227) 
Placebo (222) 
Unclear 
Karaman et al., 
2005[90] 
AD 52 MMSE 12mg/d (24) 
Placebo (20) 
High 
Ballard et al., 
2008[91]  
VaD 24 MMSE 3-12mg/d (365) 
Placebo (345) 
High 
Mok et al., 2007[92] VaD 26 MMSE 6mg/d (20) 
Placebo (20) 
Unclear 
Emre et al., 2004[93] PDD 24 MMSE 3-12mg/d (362) 
Placebo (179) 
High 
Memantine      
Fox et al., 2012[94] AD 12 MMSE 20mg/d (74) 
Placebo (79) 
Low 
Bakchine and Loft, 
2007[95] 
AD 24 ADAS-cog 20mg/d (318) 
Placebo (152) 
Low 
Peskind et al., 
2006[96] 
AD 24 ADAS-cog 20mg/d (201) 
Placebo (202) 
Low 
Wang et al., 
2013[97] 
AD 24 MMSE 20mg/d (13) 
Placebo (13) 
Unclear 
Reisberg et al., 
2003[98] 
AD 28 MMSE 20mg/d (126) 
Placebo (126) 
High 
Ashford et al., 
2011[99] 
AD 52 ADAS-cog 20mg/d (7) 
Placebo (6) 
High 
Wilkinson et al., 
2012[100] 
AD 52 MMSE 20mg/d (134) 
Placebo (144) 
Low 
Orgogozo et al., 
2002[101] 
VaD 28 MMSE 20mg/d (165) 
Placebo (156) 
High 
Wilcock et al., 
2002[102] 
VaD 28 MMSE 
ADAS-cog 
20mg/d (295) 
Placebo (284) 
Low 
Leroi et al., 
2009[103] 
PDD 16 MMSE 20mg/d (11) 
Placebo (14) 
High 
Aarsland et al., 
2009[104] 
PDD/DLB 24 MMSE 20mg/d (35) 
Placebo (40) 
Low 
Boxer et al., 
2013[105] 
FTD 26 MMSE 20mg/d (39) 
Placebo (42) 
Low 
Vercelletto et al.,  
2011[106] 
FTD 52 MMSE 20mg/d (26) 
Placebo (26) 
High 
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Table 2: Meta-regressions of effects at 3 months. Coefficients, associated p-values and omnibus test of 3 
parameters p-value provided. *=significant at 5% level. **=significant at 1% level. ref=reference 4 
category. 5 
Factor Levels Number 
of trials 
Coefficient (p-value) Omnibus test p-value 
Translation to MMSE MMSE 
ADAS-cog 
28 
32 
ref 
-0.471 (0.007) 
 
0.007** 
Risk of bias rating Low 
Unclear 
High 
8 
13 
39 
ref 
-0.371 (0.307) 
-0.346 (0.269) 
 
0.521 
Medication Donepezil 
Galantamine 
Rivastigmine 
37 
17 
6 
ref 
0.010 (0.961) 
-0.153 (0.612) 
 
0.864 
Diagnosis AD 
VaD 
PDD/DLB 
46 
6 
8 
ref 
-0.211 (0.373) 
0.806 (0.005) 
 
0.009** 
Baseline MMSE NA 55 -0.069 (0.092) 0.092 
Date Pre 2000 
2000 onwards 
26 
34 
ref 
0.068 (0.703) 
 
0.703 
 6 
 7 
Table 3: Meta-regressions of effects at 6 months. Coefficients, associated p-values and omnibus test of 8 
parameters p-value provided. *=significant at 5% level. **=significant at 1% level. ref=reference 9 
category. 10 
Factor Levels Number 
of trials 
Coefficient (p-value) Omnibus test p-value 
Translation to MMSE MMSE 
ADAS-cog 
35 
17 
ref 
0.117 (0.540) 
 
0.540 
Risk of bias rating Low 
Unclear 
High 
3 
9 
40 
ref 
0.269 (0.579) 
0.329 (0.443) 
 
0.735 
Medication Donepezil 
Galantamine 
Rivastigmine 
27 
11 
14 
ref 
0.320 (0.139) 
-0.370 (0.133) 
 
0.033* 
Diagnosis AD 39 ref  
VaD 
PDD/DLB 
9 
4 
-0.134 (0.139) 
0.970 (0.001) 
0.007* 
Baseline MMSE NA 52 -0.005 (0.869) 0.869 
Date Pre 2000 
2000 onwards 
17 
35 
ref 
-0.141 (0.456) 
 
0.456 
 1 
 2 
Figure 1: Flow diagram of trials identified for inclusion in this review through two-tier search strategy. 3 
 4 
Figure 2: Forest plot showing treatment effects from individual trials and meta-analysis results for 5 
AChEIs at 3 months after treatment initiation 6 
 7 
Figure 3: Funnel plot of treatment effects at 3 months after treatment initiation. 8 
 9 
Figure 4: Forest plot showing treatment effects from individual trials and meta-analysis results for 10 
AChEIs at 6 months after treatment initiation  11 
 12 
Figure 5: Forest plot showing treatment effects from individual trials and meta-analysis results for 13 
AChEIs at 12 months after treatment initiation 14 
 15 
Figure 6: Forest plots showing treatment effects from individual trials and meta-analysis results for 16 
memantine at 3, 6 and 12 months after treatment initiation. 17 
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